PTSGX
Price
$17.93
Change
+$0.12 (+0.67%)
Updated
Jul 31 closing price
Net Assets
1.99B
RGACX
Price
$81.63
Change
+$0.94 (+1.16%)
Updated
Jul 31 closing price
Net Assets
356.86B
Interact to see
Advertisement

PTSGX vs RGACX

PTSGX vs RGACX Comparison Chart in %
View a ticker or compare two or three
VS
PTSGX vs. RGACX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTSGX is a Buy and RGACX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGACX has more cash in the bank: 357B vs. PTSGX (1.99B). PTSGX (0.00) and RGACX (0.00) have matching dividends . PTSGX was incepted earlier than RGACX: PTSGX (26 years) vs RGACX (24 years). PTSGX (1.20) is less costly to investors than RGACX (0.93). PTSGX is a more actively managed with annual turnover of: 55.00 vs. RGACX (32.00). RGACX has a lower initial minimum investment than PTSGX: RGACX (250) vs PTSGX (2500). RGACX annual gain was more profitable for investors over the last year : 0.93 vs. PTSGX (-4.37). RGACX return over 5 years is better than : 10.91 vs. PTSGX (-11.41).
PTSGXRGACXPTSGX / RGACX
Total Expense Ratio1.160.93125%
Annual Report Gross Expense Ratio1.200.93129%
Fund Existence26 years24 years-
Gain YTD-1.0495.397-19%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.99B357B1%
Annual Yield % from dividends0.000.00-
Returns for 1 year-4.370.93-472%
Returns for 3 years51.9533.65154%
Returns for 5 years-11.4110.91-105%
Returns for 10 years14.6494.4216%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BST46.260.59
+1.29%
BlackRock Science and Technology Trust
JULB27.670.15
+0.54%
Aptus July Buffer ETF
DYLD22.26N/A
-0.02%
LeaderShares® Dynamic Yield ETF
FDEV37.15-0.31
-0.83%
Fidelity International Multifactor ETF
THNR25.40-0.47
-1.81%
Amplify Weight Loss Drug & Treatment ETF